Deciphex, a leading provider of digital pathology and AI-powered services for clinical and non-clinical pathology, today announced that it has launched it’s novel clinical diagnostics service Diagnexia.
Deciphex are pleased to announce our Gold Sponsorship of the 4th ESVP, ECVP and ESTP Cutting Edge Pathology Congress taking place on the 15th-17th of September.
This latest release of our award winning digital pathology platform delivers significant workflow improvements for our users and provides even greater support for early stage research applications through the introduction of Quantitative Pathology.
Deciphex, a leading provider of digital pathology and AI-powered services, announced that it has appointed Prof Runjan Chetty as Chief Medical Officer, Luke Benko as Vice President of Global Pathology Services and Chris Polley as Clinical Business Manager UK.
Deciphex is pleased to announce its success, in collaboration with partners Oncomark and UCD, in securing a €3m Government of Ireland, Disruptive Technologies Innovation Fund award to pursue its ongoing research program in cancer prognostics.
To take AI development in pathology to the next level, a European consortium combining leading European research centres, hospitals as well as major pharmaceutical industries, is going to develop a repository for the sharing of pathology data.
Deciphex and Charles River Laboratories International, Inc. (NYSE: CRL) have jointly announced today that they are the first in the industry to offer clients Good Laboratory Practice (GLP) validated digital peer review, using Deciphex Patholytix Preclinical for toxicologic pathology.
At Deciphex our mission is to enable our users to facilitate digital peer review of non-clinical pathology studies. We are delighted to announce the upcoming launch of Patholytix Preclinical 2.0 which provides our clients with a pathway to a regulated GLP Peer Review in conjunction with their CRO partners.
By combining Deciphex’s unique digital pathology solutions with Cernostics tissue systems pathology approach, the partnership aims to generate novel predictive indicators using AI.
To mark the recent launch of Patholytix AI 1.5, we describe how Patholyix AI fits in the technology landscape available to AI developers working on Pathology AI projects, and how the platform can benefit them in accelerating impactful data generation for their pathology stakeholders.
Deciphex an Irish based technology player, developing ergonomic digital pathology workflows and AI for histopathology, has announced the conclusion of a $6.2m Series A fundraising which will empower the company to accelerate its research and development in Artificial Intelligence and to further accelerate market entry in preclincial/toxicologic digital pathology.
We understand that many of our partners now face changing work practices and are more reliant now than ever on remote collaborative tools to manage their day to day operations. Our team remains as committed and as capable as ever to supporting you, and to help you protect business continuity.read more
Deciphex are delighted to announce the opening of its first US Facility as part of our planned US expansion.read more
Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into a partnership with Deciphex, a leading company in the provisioning of global preclinical digital pathology services...read more
Deciphex, the leading global player in the provision of global preclinical digital pathology services, announced today that it has achieved certification against ISO 27001:2013, the premier global standard for Information Security Management Systems.read more
The Patholytix preclinical solution aids improved process efficiency in preclinical toxicology by adopting a unique pattern recognition approach.read more
Deciphex an Irish based technology player, applying AI in pathology, has announced the conclusion of a €2.3m equity funding and convertible debt conversion event which will empower the company to accelerate its research and development in Artificial Intelligence and ramp up market entry in preclincial/toxicologic digital pathology.read more
Deciphex in conjunction with a number of high profile academic and industry collaborators have secured a significant grant to pursue the use of AI in colorectal cancer diagnostics and treatment.read more
Bringing pathology into digital era to speed up disease diagnosis. Startup Deciphex uses a mix of artificial intelligence and computer-aided diagnostics
- Irish Times Article - 15th November 2018
Deciphex are pleased to announce the release of their first commercial digital pathology product. Patholytix Preclinical is the first built for purpose digital pathology solution for preclinical/toxicologic pathology in pharma and clinical research organisations.read more
Deciphex and GI Partners of Illinois, LLC (a large merger of several gastroenterology practices in Illinois) have established a strategic alliance to co-develop the world’s largest database of annotated, gastrointestinal (GI), digital pathology content for deep learning purposes.read more
Deciphex in conjunction with commercial partners, Janssen Pharmaceuticals and PDS, has been awarded €2m from the EU Horizon2020, Fast Track to Innovation program, to accelerate development of artificial-intelligence based workflows for preclinical pathology.read more
Deciphex has established priority filing dates in the US on two inventions we believe will be critical to the future of Deep Learning in Pathology.read more
Deciphex is delighted to announce the closing of its first financing with support from key players in the Irish diagnostics industry.read more
Deciphex is delighted to announce its successful awarding of an SME Instrument Phase 1 grant from the EUread more
DCU Alpha Building, Innovation Campus,
11 Old Finglas Rd, Glasnevin, Co. Dublin
1012 95th Street, Naperville,
Unit S04, Exeter Science Park Centre,
6 Babbage Way, Exeter